News By Tag * Biomarker * Drug * Biomarkers * Pipeline * Consolidations * Geography * Diagnostic * Reasons * Discovery * 2010-2011 * More Tags... Industry News News By Place Country(s) Industry News
| Just Released: "Biomarkers in Drug Discovery"Fast Market Research recommends "Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly" from GBI Research, now available
Summary GBI Research, the leading business intelligence provider, has released its latest report, "Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly" ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Scope The report analyses the biomarkers in the drug discovery market along with the major forces driving the current market and the potential challenges that can restrain the growth. The scope of the report includes - * An overview of biomarkers in the drug discovery process along with their use, efficiency and limitations. * Annualized market data from 2002 and forecast forward to 2017, along with segmentation of the market into drug discovery, diagnostic and others. * Key market drivers and restraints shaping the biomarkers market. * Pipeline analysis of the biomarkers, along with segmentation by indication, phase and geography. * Competitive landscape analysis with profiling of leading companies such as Quest Diagnostics, Vermillion, Amgen, Abbott and Roche. * Analysis of partnership and M&A deals from 2010 till May 2011, along with segmentation by indication, deal type, geography and companies. Reasons to buy The report will enhance your decision making capability. It will allow you to - * Develop better strategies for biomarkers research by understanding the market dynamics of the biomarker drug discovery industry. * Develop market-entry and market expansion strategies by identifying the key areas for high growth and high opportunities. * Understand the factors shaping the biomarkers drug discovery market. * Reinforce the R&D pipeline by identifying the key biomarker tests which can provide more accurate and early diagnosis of diseases. * Identify the key players best positioned to take the advantage of the opportunities in the global biomarkers drug discovery market. * Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps. Partial Table of Contents: 1 Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Biomarkers in Drug Discovery - Introduction 2.1 Introduction 2.2 GBI Research Report Guidance 3 Biomarkers in Drug Discovery - Overview 3.1 History of Biomarkers 3.2 Biomarker Classification 3.2.1 Biomarker Categories 3.2.2 Types of Biomarkers 3.2.3 Example of Type 0, I and II Biomarker 3.2.4 Reasons Surrogate Endpoints 'Fail' 3.3 Biomarker Discovery and the Validation Process 3.3.1 Product Development Process from Discovery to Launch 3.4 General Application of Biomarkers 3.4.1 Biomarkers in Drug Discovery and Drug Development 3.4.2 Role of Biomarkers in the Drug Discovery Process 3.4.3 Application of Biomarkers in Disease Diagnosis and Prognosis 3.4.4 Potential Impact of Biomarkers on Disease States 3.4.5 Population Genetics Study 3.4.6 Environmental Health and Risk Assessment 3.4.7 Role of Biomarkers in Environmental Health and Risk Assessment 3.4.8 Toxicology Studies in Dietary Items or Nutraceuticals 3.5 Application of Biomarkers in Drug Discovery 3.5.1 Lead Identification and Optimization 3.5.2 Potential Role of Biomarkers in Lead Identification and Optimization 3.5.3 Target Validation 3.5.4 Toxicological Assay (Preclinical and Clinical) 3.5.5 Mechanism of Action 3.5.6 Monitor Therapy and Dose Response 3.5.7 Stratify Patient Population 3.5.8 Filing and Post Marketing Surveillance 3.6 Benefits of Biomarker Utilization 3.6.1 Disease Understanding 3.6.2 Project Prioritization through Early Attrition 3.6.3 Streamlining Clinical Trials 3.6.4 Reducing Cost of Drug Development 3.6.5 Speeding Drug Development 3.6.6 Avoiding Adverse Drug Reactions (ADR) and Rationalizing Dosing Regimen 3.6.7 Drug Repositioning 3.7 Challenges in Biomarker Utilization 3.7.1 Variability 3.7.2 Validity 3.7.3 Measurement Errors 4 Biomarkers in Drug Discovery - Case Study 4.1 Cell Signaling Technology Enters Into Co-Marketing Agreement with Astellas Pharma 4.1.1 Definition 4.1.2 About Lung Cancer 4.1.3 Company Profile 4.1.4 Technology Used 4.1.5 Market Information 4.1.6 Advantages 4.1.7 Future Prospect 5 Biomarkers in Drug Discovery - Market Characterization 5.1 Market Overview 5.2 Market Size and Forecasts Full Table of Contents is available at: -- http://www.fastmr.com/ About GBI Research GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. View more research from GBI Research at http://www.fastmr.com/ About Fast Market Research Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156. # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number